193 related articles for article (PubMed ID: 35313504)
1. Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Li LH; Liesenborghs L; Wang L; Lox M; Yakass MB; Jansen S; Rosales Rosas AL; Zhang X; Thibaut HJ; Teuwen D; Neyts J; Delang L; Dallmeier K
Mol Ther Methods Clin Dev; 2022 Jun; 25():215-224. PubMed ID: 35313504
[TBL] [Abstract][Full Text] [Related]
2. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
3. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
4. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Sanchez-Felipe L; Vercruysse T; Sharma S; Ma J; Lemmens V; Van Looveren D; Arkalagud Javarappa MP; Boudewijns R; Malengier-Devlies B; Liesenborghs L; Kaptein SJF; De Keyzer C; Bervoets L; Debaveye S; Rasulova M; Seldeslachts L; Li LH; Jansen S; Yakass MB; Verstrepen BE; Böszörményi KP; Kiemenyi-Kayere G; van Driel N; Quaye O; Zhang X; Ter Horst S; Mishra N; Deboutte W; Matthijnssens J; Coelmont L; Vandermeulen C; Heylen E; Vergote V; Schols D; Wang Z; Bogers W; Kuiken T; Verschoor E; Cawthorne C; Van Laere K; Opdenakker G; Vande Velde G; Weynand B; Teuwen DE; Matthys P; Neyts J; Jan Thibaut H; Dallmeier K
Nature; 2021 Feb; 590(7845):320-325. PubMed ID: 33260195
[TBL] [Abstract][Full Text] [Related]
5. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
6. Visualization of yellow fever virus infection in mice using a bioluminescent reporter virus.
Dong HL; Wang HJ; Liu ZY; Ye Q; Qin XL; Li D; Deng YQ; Jiang T; Li XF; Qin CF
Emerg Microbes Infect; 2021 Dec; 10(1):1739-1750. PubMed ID: 34379047
[TBL] [Abstract][Full Text] [Related]
7. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
[TBL] [Abstract][Full Text] [Related]
9. YF17D-based vaccines - standing on the shoulders of a giant.
Sanchez-Felipe L; Alpizar YA; Ma J; Coelmont L; Dallmeier K
Eur J Immunol; 2024 May; 54(5):e2250133. PubMed ID: 38571392
[TBL] [Abstract][Full Text] [Related]
10. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
[TBL] [Abstract][Full Text] [Related]
11. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
12. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Rafferty E; Duclos P; Yactayo S; Schuster M
Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
[TBL] [Abstract][Full Text] [Related]
13. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice.
Boudewijns R; Ma J; Neyts J; Dallmeier K
JHEP Rep; 2021 Aug; 3(4):100295. PubMed ID: 34159304
[TBL] [Abstract][Full Text] [Related]
14. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge.
Lemmens V; Kelchtermans L; Debaveye S; Chiu W; Vercruysse T; Ma J; Thibaut HJ; Neyts J; Sanchez-Felipe L; Dallmeier K
NPJ Vaccines; 2023 Jul; 8(1):99. PubMed ID: 37433816
[TBL] [Abstract][Full Text] [Related]
15. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
16. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.
Mudd PA; Piaskowski SM; Neves PC; Rudersdorf R; Kolar HL; Eernisse CM; Weisgrau KL; de Santana MG; Wilson NA; Bonaldo MC; Galler R; Rakasz EG; Watkins DI
Immunogenetics; 2010 Sep; 62(9):593-600. PubMed ID: 20607226
[TBL] [Abstract][Full Text] [Related]
17. A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses.
Oreshkova N; Myeni SK; Mishra N; Albulescu IC; Dalebout TJ; Snijder EJ; Bredenbeek PJ; Dallmeier K; Kikkert M
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960238
[TBL] [Abstract][Full Text] [Related]
18. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
Jiang X; Dalebout TJ; Bredenbeek PJ; Carrion R; Brasky K; Patterson J; Goicochea M; Bryant J; Salvato MS; Lukashevich IS
Vaccine; 2011 Feb; 29(6):1248-57. PubMed ID: 21145373
[TBL] [Abstract][Full Text] [Related]
19. The yellow fever 17D virus as a platform for new live attenuated vaccines.
Bonaldo MC; Sequeira PC; Galler R
Hum Vaccin Immunother; 2014; 10(5):1256-65. PubMed ID: 24553128
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.
Franco D; Li W; Qing F; Stoyanov CT; Moran T; Rice CM; Ho DD
Vaccine; 2010 Aug; 28(35):5676-85. PubMed ID: 20600494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
